SOURCE-LINKED STUDY SUMMARY
Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial.
Abstract summarizedQuality not appraised
- What was studied
- This phase II trial tested whether elamipretide improved cardiac structure and function in stable heart failure with reduced ejection fraction.
- Who / model studied
- Seventy-one patients had stable heart failure and left-ventricular ejection fraction of 40% or lower.
- Studied dose & schedule
- Participants received placebo, 4 mg elamipretide, or 40 mg elamipretide subcutaneously once daily for 28 consecutive days in a double-blind comparison.
- What the study found
- Neither dose improved LVESV versus placebo: difference of means was −0.3 mL for 4 mg and 2.3 mL for 40 mg; confidence intervals crossed zero.
- Limitations & context
- Treatment lasted four weeks and centered on imaging outcomes. Drug-related adverse-event rates were similar across groups, but longer clinical outcomes were not tested.
Read summary source ↗ · Prepared 10/6/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/j.cardfail.2020.02.001